Civica’s $27.8m New Facility Expands Virginia Drug Hub Vision
Meanwhile, CivicaScript Targets Prostate Cancer With First Product Launch
Civica has announced a further $27.8m investment to support its plans for insulin and other essential medicines. The news comes shortly after CivicaScript announced its first launch in the form of abiraterone tablets.
You may also be interested in...
Civica has selected Profil as its clinical partner as it develops its affordable range of biosimilar insulins, and has also added pharmacy benefit manager EmsanaRx to its generic CivicaScript network.
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.